JS 104
Alternative Names: JS-104Latest Information Update: 06 Mar 2024
At a glance
- Originator Risen Pharma
- Developer Risen Pharma; Shanghai Junshi Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 06 Mar 2024 JS 104 is still in preclinical development for Breast cancer in China (PO) (Shanghai Junshi Biosciences Pipeline, March 2024)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Breast-cancer in China (PO)